Gatifloxacin: Difference between revisions
No edit summary |
No edit summary |
||
| Line 18: | Line 18: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
''' [[Gatifloxacin description|Description]]''' | ''' [[Gatifloxacin description|Description]]''' | ||
'''| [[ | '''| [[Gatifloxacin clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Gatifloxacin microbiology|Microbiology]]''' | '''| [[Gatifloxacin microbiology|Microbiology]]''' | ||
'''| [[Gatifloxacin indications and usage|Indications and Usage]]''' | '''| [[Gatifloxacin indications and usage|Indications and Usage]]''' | ||
'''| [[Gatifloxacin contraindications|Contraindications]]''' | '''| [[Gatifloxacin contraindications|Contraindications]]''' | ||
'''| [[Gatifloxacin warnings|Warnings | '''| [[Gatifloxacin warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[Gatifloxacin adverse reactions|Adverse Reactions]]''' | '''| [[Gatifloxacin adverse reactions|Adverse Reactions]]''' | ||
'''| [[Gatifloxacin clinical studies|Clinical Studies]]''' | '''| [[Gatifloxacin clinical studies|Clinical Studies]]''' | ||
'''| [[Gatifloxacin dosage and administration|Dosage and Administration]]''' | '''| [[Gatifloxacin dosage and administration|Dosage and Administration]]''' | ||
Revision as of 21:47, 8 January 2014
| Gatifloxacin |
|---|
| GATIFLOXACIN®,ZYMAXID®,ZYMAR® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Clinical Studies |
| Dosage and Administration |
| How Supplied |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
For patient information, click here.
Overview
Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterialenzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin® for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan then withdrawn from the market in 2006. Allergan produces an eye-drop formulation called Zymar®. and Zymaxid .
Category
Fluoroquinolone, fourth generation.
US Brand Names
ZYMAXID®, ZYMAR®, GATIFLOXACIN.
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
References
http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1160b16c-929a-4e85-9c0b-1d8c96a7678b